隐形牙套制造商Byte因患者报告的严重牙齿损伤和颌骨问题，于2024年停止向澳大利亚客户销售1。该公司的产品在获得澳大利亚医疗用品管理局（TGA）批准时仅用时3天且未经审计1，随后监管漏洞进一步被曝光。
不良事件报告数量的急剧增加凸显了问题的严重性。截至2024年11月，Byte累计仅收到2份不良事件报告，但随后一个月内该数字增至77份1。这些不良事件报告涉及牙齿断裂、颌骨锁定、骨质流失和牙龈衰退等多种伤害1。患者为接受治疗支付了3300至3700澳元1，却因器械失效或造成的伤害而无法获得牙医协助1。
监管缺陷的范围远超Byte一家公司。TGA对超过28000种低风险医疗器械基本无监督1，制造商虽然需要在30天内提交不良事件报告，但并无强制执行机制1。自2012年以来，第一类医疗器械共产生5424份不良事件报告，其中包括714起伤害事件和24例死亡1。
Clear aligner company Byte ceased selling to Australian customers in 2024 following a dramatic spike in reports of serious dental and jaw complications, according to an investigation into the company's regulatory oversight.1 The withdrawal exposed significant gaps in how Australia's Therapeutic Goods Administration (TGA) monitors low-risk medical devices, with the regulator overseeing more than 28,000 such products with minimal active supervision.1
Byte's troubles began despite a remarkably swift approval process. The company received regulatory clearance in July 2022 after just three days of review, with no independent audit conducted.1 By November 2024, the company had reported only two adverse events to authorities; within the following month, that figure surged to 77 reports.1 The complaints documented broken teeth, locked jaws, bone loss, and gum deterioration among patients who had paid between $3,300 and $3,700 for treatment.1 Many patients reported being unable to obtain dental assistance once the aligners caused injury or failed to function as intended.1
The case reflects broader regulatory vulnerabilities. Since 2012, Class I medical devices in Australia have generated 5,424 adverse event reports overall, including 714 instances of harm and 24 deaths.1 While manufacturers are required to submit adverse event reports within 30 days, the TGA has no enforcement mechanism to ensure compliance, allowing companies to self-determine whether incidents warrant reporting.1
评论
还没有评论，欢迎留下第一条。